Dr. María-Victoria Mateos, a leading myeloma researcher, explores the excitement surrounding advances in the management of newly diagnosed elderly patients and the hope for a new standard of care. Dr. Mateos also provides an overview of the Phase III VISTA (Velcade as Initial Standard Therapy) trial and discusses its impact on long-term survival. Dr. Mateos explains how maintenance therapy with Velcade (bortezomib), dose and schedule modifications, and the management of adverse events are all vital factors in maximizing treatment and providing improved overall survival.
Related Videos In Multiple Myeloma
María-Victoria Mateos, EHA 2020: TOURMALINE-MM4 study
Dr María-Victoria Mateos, (Associate Professor of Medicine, Director of Myeloma Unit, University Hospital of Salamanca, Salamanca, Spain) explores unmet needs in the treatment of patients with newly-diagnosed multiple myeloma, and discusses the major findings of the TOURMALINE-MM4 study and the potential of ixazomib in patients no undergoing autologous stem cell transplant. Questions: What are the limitations […]
Shaji Kumar, ASCO20: Efficacy and Toxicity in the Randomised Phase III ENDURANCE Trial in Myeloma
We are joined by touchONCOLOGY’s Oncology & Hematology Review (US) Editor-in-Chief Shaji Kumar, Mayo Clinic, to discuss his plenary session at ASCO20 on the efficacy and toxicity in the randomized phase III ENDURANCE trial of the use of bortezomib, lenalidomide and dexamethasone for initial therapy of newly diagnosed multiple myeloma. Questions 1. What is the […]
Patrick Laroche, ASCO20: Bispecific Antibodies in the Treatment of Multiple Myeloma
Patrick Laroche, EMEA Therapeutic Area Leader Hematology at Janssen Pharmaceutica, discusses the benefits of new bispecific antibodies and how he sees the future of multiple myeloma treatment evolving over the coming years. Click here to view Patrick Laroche discussing the potential of CAR-T treatment JNJ-4528 in multiple myeloma Questions 1. Could you tell us more […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!